These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 28049654)

  • 21. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
    Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
    J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone H3 peptide based LSD1-selective inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
    Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cadmium induces histone H3 lysine methylation by inhibiting histone demethylase activity.
    Xiao C; Liu Y; Xie C; Tu W; Xia Y; Costa M; Zhou X
    Toxicol Sci; 2015 May; 145(1):80-9. PubMed ID: 25673502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting histone lysine demethylases by truncating the histone 3 tail to obtain selective substrate-based inhibitors.
    Lohse B; Nielsen AL; Kristensen JB; Helgstrand C; Cloos PA; Olsen L; Gajhede M; Clausen RP; Kristensen JL
    Angew Chem Int Ed Engl; 2011 Sep; 50(39):9100-3. PubMed ID: 21919140
    [No Abstract]   [Full Text] [Related]  

  • 26. Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.
    Zhou C; Wu F; Lu L; Wei L; Pai E; Yao Y; Song Y
    PLoS One; 2017; 12(2):e0170301. PubMed ID: 28158205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-based assays to support the profiling of small molecules with histone methyltransferase and demethylase modulatory activity.
    Martinez NJ; Simeonov A
    Drug Discov Today Technol; 2015 Nov; 18():9-17. PubMed ID: 26723887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
    Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
    J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone lysine demethylases as targets for anticancer therapy.
    Højfeldt JW; Agger K; Helin K
    Nat Rev Drug Discov; 2013 Dec; 12(12):917-30. PubMed ID: 24232376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone demethylation and steroid receptor function in cancer.
    Stratmann A; Haendler B
    Mol Cell Endocrinol; 2012 Jan; 348(1):12-20. PubMed ID: 21958694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression, Purification, and Biochemical Analysis of the LSD1/KDM1A Histone Demethylase.
    Laurent B; Shi Y
    Methods Enzymol; 2016; 573():241-59. PubMed ID: 27372756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone lysine methylation and demethylation pathways in cancer.
    Varier RA; Timmers HT
    Biochim Biophys Acta; 2011 Jan; 1815(1):75-89. PubMed ID: 20951770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors.
    Zheng YC; Chang J; Zhang T; Suo FZ; Chen XB; Liu Y; Zhao B; Yu B; Liu HM
    Curr Med Chem; 2017; 24(23):2496-2504. PubMed ID: 28486922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-throughput screening to identify inhibitors of lysine demethylases.
    Gale M; Yan Q
    Epigenomics; 2015; 7(1):57-65. PubMed ID: 25687466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
    Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R
    J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Annual review of LSD1/KDM1A inhibitors in 2020.
    Fu DJ; Li J; Yu B
    Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The emerging roles of histone demethylases in cancers.
    Tong D; Tang Y; Zhong P
    Cancer Metastasis Rev; 2024 Jun; 43(2):795-821. PubMed ID: 38227150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
    Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
    Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro histone demethylase assay.
    Tsukada Y; Nakayama KI
    Cold Spring Harb Protoc; 2010 Oct; 2010(10):pdb.prot5512. PubMed ID: 20889709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening assays for epigenetic targets using native histones as substrates.
    Hauser AT; Bissinger EM; Metzger E; Repenning A; Bauer UM; Mai A; Schüle R; Jung M
    J Biomol Screen; 2012 Jan; 17(1):18-26. PubMed ID: 21965113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.